Soros Fund Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Soros Fund Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-107,308	Closed	-$1.3M	–	288
2015 Q1	$1.3M	Buy	+107,308	New	+$1.01M	0.01%	201

Other funds holding SUPN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MRM

Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KIA

Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Soros Fund Management's SUPN Position: Q2 2015 in Review

Soros Fund Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 107,308 shares — an estimated $1.3M sold.

Soros Fund Management first reported a position in SUPN in Q1 2015 and held it in 1 quarter. The position peaked at $1.3M in Q1 2015. 165 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

Soros Fund Management reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Soros Fund Management sold 107,308 Supernus Pharmaceuticals shares in Q2 2015, an estimated $1.3M.
Soros Fund Management first reported a position in Supernus Pharmaceuticals in Q1 2015 and held it in 1 quarter.
Soros Fund Management's Supernus Pharmaceuticals position peaked at $1.3M in Q1 2015.
165 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Soros Fund Management's 13F filing for Q2 2015, filed 14 Aug 2015.